Views and Attitudes of Oncologists and Geriatricians on the Use of Chemotherapy and Hormone Therapy in Treating Older and/or Frail Women With Breast Cancer
RATIONALE: A patient's age, health, and ability to perform daily activities may affect which treatment options are offered by doctors to older and/or frail women with breast cancer.
PURPOSE: This clinical trial is studying the views and attitudes of oncologists and geriatricians on the use of chemotherapy and hormone therapy in treating older and/or frail women with breast cancer.
|Study Design:||Primary Purpose: Health Services Research|
|Official Title:||Perspectives and Attitudes on the Use of Adjuvant Chemotherapy and Hormonal Therapy in Older and/or Frail Women: A Survey of Oncologists and Geriatricians|
- Attitudes and perspectives of health professionals [ Designated as safety issue: No ]
- Homogeneity of treatment recommendations [ Designated as safety issue: No ]
- Relative impact of chronological age, baseline health, and functional status on treatment recommendations [ Designated as safety issue: No ]
|Study Start Date:||December 2006|
|Study Completion Date:||October 2007|
|Primary Completion Date:||October 2007 (Final data collection date for primary outcome measure)|
- Evaluate the attitudes and perspectives of 150 oncologists and 150 geriatricians or primary care providers regarding the adjuvant treatment of older women with breast cancer of varying ages, health, and functional status.
- Determine whether homogeneity exists in treatment recommendations.
- Determine the relative impact of chronological age, baseline health, and functional status on treatment recommendations.
OUTLINE: Participants complete a 25-minute online survey regarding their treatment recommendations for older women with breast cancer of varying ages, health, and functional status.
PROJECTED ACCRUAL: A total of 300 participants will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00478283
|Principal Investigator:||Arti Hurria, MD||Beckman Research Institute|